Patient Guide · Peptide Therapy

How Long to Cycle Peptides

What cycling actually means, which peptides genuinely need a break, and the course lengths we run at Olympia Aesthetics & Wellness in Palm Harbor.

Reviewed by Oliver Morris, DO · Medical Director

“How long do I cycle this?” is the question we get more than any other about peptides, and it usually arrives with three different answers already collected from three different forums. The confusion is understandable, because the word cycling gets used loosely to mean anything from two days off a week to two months off between courses.

There is a better question underneath it. Not how long, but why would this particular peptide need a break at all? Some peptides genuinely lose their effect if you never stop, for reasons rooted in how receptors behave. Others do not lose anything, and the reason you stop is simply that the job is finished. Those are two completely different situations, and treating them the same way is how people end up injecting something for eight months with no plan and no idea whether it is still doing anything.

The numbers on this page are the protocols we actually run. They are pulled from our own peptide protocol pages, not from a generic chart. If your protocol differs from what you read here, yours is the one that counts, because it was built around your labs and your goals.

None of the peptides on this page are FDA-approved for the uses described. Clinical use is off-label and investigational, and it belongs under the supervision of a licensed provider who knows your history and can order labs. This is patient education for people already working with a provider. It is not a protocol to run on your own.

The mechanism

Why a break matters for some peptides and not others

Receptors are not passive locks waiting for a key. When a receptor is stimulated continuously, the cell turns down the volume. It modifies the receptor so it stops passing the signal along, pulls it inside the cell where the peptide cannot reach it, and over longer stretches simply builds fewer of them. The clinical result is that the same dose stops producing the same effect. Pharmacology calls this desensitization, or tachyphylaxis when it develops quickly.

The peptides where this matters most are the growth hormone secretagogues. Ipamorelin acts on the ghrelin receptor, and CJC-1295 and tesamorelin act on the growth hormone releasing hormone receptor. Both pathways are built around pulses. Your pituitary normally releases growth hormone in bursts, mostly overnight, with quiet stretches in between, and that rhythm is part of the signal. Flooding those receptors continuously works against the very pattern you are trying to restore. This is also why we dose those two protocols nightly on a five-days-on, two-days-off schedule rather than seven days a week. The weekly break is a small-scale version of the same idea.

Now contrast that with BPC-157. It is a repair peptide, and the mechanisms described for it involve tissue healing and blood vessel formation rather than one receptor being hammered into submission. There is no well described desensitization story for it. So a BPC-157 course does not end because it stopped working. It ends because the tendon healed, or it did not, and either way you have your answer. That is a course, not a cycle.

A third pattern shows up with GHK-Cu. The limiting factor there is not receptor behavior at all, it is copper. GHK-Cu carries copper into the body, and copper is a mineral you have finite capacity to handle. A break in a GHK-Cu protocol is about not accumulating copper across long uninterrupted stretches, which is a different reason to stop than anything happening at a receptor.

Quick reference

Our protocols, side by side

This is what we run in Palm Harbor. Individual protocols get adjusted, but these are the defaults.

Protocol	Frequency	Cycle	Why the break exists
MOTS-c	2 to 3 times weekly	8 to 12 weeks	Dosing is already intermittent. The break is precautionary and gives a clean window to re-measure metabolic markers off the peptide.
CJC-1295 with Ipamorelin	Nightly, 5 on and 2 off	12 weeks on, 4 off	Genuine receptor desensitization risk at both receptors. The break restores sensitivity and lets natural pulsatility resume.
Tesamorelin with Ipamorelin	Nightly, 5 on and 2 off	12 weeks on, 4 off	Same receptor logic. The break also lets IGF-1 drift back toward baseline so the next lab draw means something.
BPC-157	Once daily, 5 on and 2 off	4 to 8 weeks	Not a true cycle. No described desensitization. The endpoint is tissue healing, so the course ends when the injury resolves or clearly has not.
Wolverine Stack (BPC-157 and TB-500)	Once daily	4 to 8 weeks	Goal-directed. Four weeks for an acute issue, eight for something longer-standing, then a break before deciding whether to repeat.
Glow Protocol (GHK-Cu, BPC-157, TB-500)	Once daily	8 to 12 weeks	The GHK-Cu component sets the schedule. Skin and tissue remodeling is slow, so the course is long and the break follows it.
GHK-Cu	Once daily, 5 on and 2 off	8 to 12 weeks	Copper handling sets the ceiling, not receptor fatigue.
Selank	Daily	1 to 2 weeks on	Used as a short course during anxious or high-stress stretches rather than continuously. Extended breaks between courses.
Semax	Daily	2 to 4 weeks on	The focus and drive effect is widely reported to blunt with continuous daily use. Short courses during demanding periods, with extended breaks.
NAD+	Daily subcutaneous or weekly IV	Variable by goal	Loading series of several weeks, then maintenance. Driven by goal rather than by a fixed cycle.

Be skeptical of confident numbers, including ours. These lengths come from clinical practice and pharmacologic reasoning, not from randomized trials comparing eight weeks against twelve. Nobody has run that study for most of these compounds. Anyone quoting a precise optimal cycle length, on any website, is extrapolating.

Peptide by peptide

Where the reasoning differs

MOTS-c. This gets asked about more than anything else, and the honest answer is that it does not need cycling the way a growth hormone secretagogue does. MOTS-c is encoded in mitochondrial DNA and acts largely through AMPK, the same energy-sensing pathway that exercise and caloric restriction work through. No receptor desensitization problem has been established for it. We still run it in defined 8 to 12 week courses for two better reasons. The human safety record is short, so limiting continuous exposure is reasonable caution. And more practically, you cannot tell whether it is helping if you never stop. A break gives you a clean baseline to compare against. Our MOTS-c page covers what it is being studied for.

The growth hormone peptides. CJC-1295 with ipamorelin and tesamorelin with ipamorelin are the group where cycling has real pharmacologic teeth, and both run 12 weeks on with a 4 week break. Patients who stay on continuously tend to describe the same arc. Sleep improves, recovery improves, body composition shifts, and then somewhere past the two or three month mark the benefits flatten. That plateau is the tell. Pushing through it at a higher dose usually deepens the problem rather than solving it, because you are leaning harder on receptors that are already turned down.

The repair peptides. BPC-157 alone, or paired with TB-500 as the Wolverine Stack, is best understood as a treatment course for a specific problem. You are treating a shoulder, a tendon, a gut issue. Four weeks is a reasonable window for something acute and eight for something that has been there a while. If the answer is yes and the problem resolved, you stop. If it improved but is not finished, a break and a second course is defensible. If eight weeks produced nothing, a twelve week course is unlikely to change that, and it is time to reconsider the diagnosis rather than the dose.

The nootropic peptides. Selank and Semax are the shortest courses we run, at 1 to 2 weeks and 2 to 4 weeks respectively. Both were developed and studied in Russia in short courses, and neither was ever designed around continuous indefinite use. Semax in particular has a consistent pattern of reports that the cognitive effect fades with daily use and returns after time off. We use both as tools for a defined stretch, a demanding work period or an anxious season, rather than as something you stay on.

GHK-Cu and the Glow Protocol. Both run 8 to 12 weeks, which is longer than people expect for a skin protocol. Collagen and tissue remodeling are genuinely slow processes and a four week course would stop before the interesting part. The copper question is what caps it at twelve rather than letting it run indefinitely.

The decision

How we decide to stop, continue, or change

A calendar is the weakest possible reason to make this call. Here is the sequence that actually works.

Define the endpoint before you start. What specifically is supposed to change, and how will you know? “Feel better” is not measurable. Sleep quality, shoulder range of motion, waist circumference, a lab value, a training benchmark. Write it down at the start, because memory is generous.
Get a baseline. For growth hormone peptides that means an IGF-1 level before the first dose. Without a starting number, a mid-course IGF-1 tells you very little. For metabolic goals it means fasting glucose, A1c, lipids, and body composition. For a repair course it means an honest functional assessment of the area.
Re-check partway through. Four to six weeks is the usual point. Early enough to change course without having spent the whole cycle.
Read a plateau as information. If effects that were clearly there at week four are fading by week ten on a secretagogue, that is desensitization behaving exactly as predicted. The answer is the scheduled break, not more drug.
Compare against baseline at the end. Same labs, same measurements, same conditions. This is the step people skip, and skipping it means the next cycle gets planned on impressions rather than data.
Then decide. Clear benefit and clean labs argues for another cycle after the break. Benefit that faded despite a break argues for changing the compound, or for looking harder at sleep, training, and nutrition. No benefit at all argues for stopping, because continuing to inject something that did nothing is expense with risk attached.

The risk of never stopping

What happens when you don’t cycle

With growth hormone secretagogues, the usual outcome is not a dramatic complication. It is diminishing returns. The peptide quietly stops doing what it did, and because the fade is gradual, people often blame their sleep or their training and increase the dose instead. IGF-1 sitting elevated for long uninterrupted periods is also worth watching on its own terms, and an elevated IGF-1 is a specific reason we would shorten a course or extend a break.

With repair peptides, the risk of open-ended use is simpler. You are accepting unknown long-term exposure to a compound without long-term human safety data, in exchange for a benefit you have most likely already collected. “We do not know” is exactly why indefinite use is hard to justify.

With the nootropic peptides, the failure mode is that you lose your own baseline. If you have been on Semax daily for six months, you no longer know what your unmedicated focus feels like, which makes it impossible to judge whether the peptide is still earning its place.

The thing that gets lost across all three categories is the ability to interpret anything. Labs drawn during month seven of continuous use, with no baseline and no off period, are very hard to act on.

How we source, plainly. Our peptides come from a distributor that provides a certificate of analysis on each lot confirming identity, purity, and concentration, and they are labeled for research use. We are direct about that because you should know what you are being given and under what framework. Peptides here are used inside a supervised program with baseline labs, a defined cycle, and follow-up. We do not sell vials to walk-in buyers.

Guiding the plan

How labs and symptoms steer the decision

For anything touching the growth hormone axis, IGF-1 is the workhorse. It is stable enough to measure reliably, it reflects the downstream effect of the peptide, and a before-and-after pair tells you whether the protocol did something biological. Alongside it we look at fasting glucose and A1c, because growth hormone signaling affects insulin sensitivity and that is the trade-off worth tracking.

For metabolic goals the panel is metabolic: fasting glucose, A1c, lipids, and objective body composition rather than scale weight. For repair courses, labs matter less and function matters more, so the endpoint is range of motion, pain, and whether you can do the thing you could not do before.

Symptoms carry real weight too, sometimes more than labs. Water retention, tingling in the hands, joint aching, or morning grogginess on a growth hormone peptide are dose signals worth acting on before the next draw. A flat or blunted response on a nootropic peptide means the course has run long enough. If a peptide made you feel worse rather than better, that is not something to push through.

Questions about your own protocol are best answered with your chart open rather than from a page on the internet. Call us at (727) 274-1972 and we can go through what you are running and whether the timing still makes sense.

Common Questions

Questions we actually get asked

How long can you cycle MOTS-c?

Our MOTS-c protocol runs 8 to 12 weeks, dosed two to three times weekly, followed by a break before deciding whether to repeat. There is no trial data establishing an optimal duration for MOTS-c, so that range comes from clinical practice and pharmacologic reasoning rather than from published head-to-head comparisons. The practical reason to stop is that you want a clean off-period to re-measure fasting glucose, A1c, lipids, and body composition, and see whether the peptide actually changed anything. Running it continuously removes your ability to answer that question.

Does MOTS-c need to be cycled?

Not for the reason most people assume. MOTS-c acts largely through AMPK, an energy-sensing pathway, and no receptor desensitization or tolerance problem has been established for it the way it has for growth hormone secretagogues. It gets cycled for two other reasons. Human safety data on long continuous use is limited, so capping exposure is reasonable caution. And a break gives you a baseline to compare against so you can judge whether it is helping. So cycling MOTS-c is prudent practice rather than a pharmacologic requirement.

How long is a Wolverine Stack cycle?

We run the Wolverine Stack, which combines BPC-157 and TB-500 in one daily subcutaneous injection, for 4 to 8 weeks. Four weeks is typical for a recent strain and eight for a longer-standing problem like a persistent tendinopathy or post-surgical recovery, with a break before deciding whether to repeat. The break is not about tolerance, since neither peptide has a well described desensitization mechanism. It exists because long-term human safety data does not exist for either compound. If eight weeks produced no functional improvement, extending the course is less useful than revisiting the diagnosis.

How long do you cycle CJC-1295 and ipamorelin?

Our protocol is 12 weeks on followed by a 4 week break, dosed nightly on a five-days-on, two-days-off schedule. This is the group where cycling has genuine pharmacologic justification, because ipamorelin acts on the ghrelin receptor and CJC-1295 on the growth hormone releasing hormone receptor, and continuous stimulation of either leads to desensitization. The weekly two days off and the four week break between courses are both aimed at the same thing, which is preserving receptor sensitivity and letting your own pulsatile growth hormone release resume. If benefits flatten around the two or three month mark, that is the expected pattern, and the answer is the scheduled break rather than a higher dose.

How do you cycle Selank and Semax?

Both are short courses rather than ongoing therapy. We run Selank for 1 to 2 weeks at a time and Semax for 2 to 4 weeks, both dosed daily, with extended breaks between courses. Both were developed and studied in Russia in short courses and neither was designed around continuous indefinite use. Semax in particular has a consistent pattern of reports that the focus effect blunts with continuous daily use and returns after time off. We use them as tools for a defined stretch, such as a demanding work period or an anxious season, rather than as something you stay on. We use the injectable subcutaneous form in this practice, though most published research on both used the intranasal route.

What is the cycle for the Glow Protocol?

The Glow Protocol combines GHK-Cu, BPC-157, and TB-500 in a single daily subcutaneous injection, and we run it for 8 to 12 weeks with a break between courses. That is longer than people expect for a skin protocol, and the reason is that collagen and tissue remodeling are slow. A four week course would stop before the part you are actually paying for. What caps it at twelve rather than letting it run indefinitely is the GHK-Cu component, because copper is a mineral the body has limited capacity to clear, so the break is a mineral-handling consideration rather than a receptor one.

Not sure where you are in your cycle?

If you are running a protocol and cannot remember when you started or when you are supposed to stop, that is worth a phone call. We can review what you are on and whether the timing still fits your goals.

Book a consultation
Physician-supervised peptide care in Palm Harbor. Call (727) 274-1972.

Medically reviewed

Reviewed by Oliver Morris, DO, Medical Director at Olympia Aesthetics & Wellness, 33295 US Hwy 19 N, Suite 109, Palm Harbor, FL 34684. Last reviewed July 2026. None of the peptides described here are FDA-approved for these uses. Clinical use is off-label and investigational, and this page is patient education rather than a protocol to follow independently. Cycle lengths reflect our clinical practice and are individualized after evaluation and labs.

Follow us